Percutaneous Coronary Intervention Therapeutics
1. Angiomax patent expiration
Treatment: Inhibition of thrombin in a patient
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5196404 (Pediatric) | SANDOZ | Inhibitors of thrombin |
Jun, 2015
(10 years ago) | |
| US5196404 | SANDOZ | Inhibitors of thrombin |
Dec, 2014
(11 years ago) | |
| US7582727 | SANDOZ | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jul, 2028
(2 years from now) | |
| US7598343 | SANDOZ | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jul, 2028
(2 years from now) | |
|
US7582727 (Pediatric) | SANDOZ | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jan, 2029
(3 years from now) | |
|
US7598343 (Pediatric) | SANDOZ | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jan, 2029
(3 years from now) | |
Drugs and Companies using BIVALIRUDIN ingredient
Market Authorisation Date: 15 December, 2000
Dosage: INJECTABLE
How can I launch a generic of ANGIOMAX before it's drug patent expiration?
More Information on Dosage
ANGIOMAX family patents
2. Kengreal patent expiration
Treatment: P2y12 platelet inhibitor for use as adjunct to percutaneous coronary intervention to reduce risk of various diseases/conditions in patients ...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6114313 | CHIESI | Pharmaceutical compositions for freeze drying |
Dec, 2018
(7 years ago) | |
| US6130208 | CHIESI | Formulation containing a nucleotide analogue |
Jun, 2023
(2 years ago) | |
| US8759316 | CHIESI | Maintenance of platelet inhibition during antiplatelet therapy |
May, 2029
(3 years from now) | |
| US10039780 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(9 years from now) | |
| US9427448 | CHIESI | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
Nov, 2030
(4 years from now) | |
| US9925265 | CHIESI | Methods of treating or preventing stent thrombosis |
May, 2029
(3 years from now) | |
| US8680052 | CHIESI | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
Mar, 2033
(7 years from now) | |
| US9439921 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(9 years from now) | |
| US9700575 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(9 years from now) | |
| US9295687 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 22, 2020 |
Drugs and Companies using CANGRELOR ingredient
NCE-1 date: 23 June, 2019
Market Authorisation Date: 22 June, 2015
Dosage: POWDER
How can I launch a generic of KENGREAL before it's drug patent expiration?
More Information on Dosage
KENGREAL family patents